Organization
Sandoz, Inc.
Topic
All Topics
People
Find news about people
Alumni
Find news on alumni of any org
Industries
Find news on a particular market
Your Contacts
Find news on your contacts
Sign up for free daily alerts on this feed:
By pressing Sign Up, you agree to our Terms of Use, Privacy Policy, and the LexisNexis Terms & Conditions

Follow

Change Feed
Sandoz, Inc.
... President and Chief Executive Officer of Momenta Pharmaceuticals. Wheeler continued, 'Operationally, with Sandoz's launch of Glatopa 40 mg we should gain more clarity on this ...
... President and Chief Executive Officer of Momenta Pharmaceuticals. Wheeler continued, "Operationally, with Sandoz's launch of Glatopa 40 mg we should gain more clarity on this ...
... Novartis's Sandoz division has won U.S. approval for a larger dosage of its Glatopa ...
... After last week’s FDA rejection for Sandoz’s generic Advair, Novartis’ copycat arm needed a win. And it got a ...
... Sandoz, a Novartis division, today announced the US FDA approval and launch of ...
... today announced that the U.S. Food and Drug Administration (FDA) has approved Sandoz's Abbreviated New Drug Application for Glatopa (glatiramer acetate injection) 40 mg/mL and ...
... drugmaker now says it’s “highly unlikely” the generic will launch this year. Sandoz’ version is the third to be turned away by the FDA. RELATED: ...
... Ken Ren, Ph.D., CASI's Chief Executive Officer commented, 'The acquisition of the Sandoz ANDAs enhances our strategic focus to build a robust pipeline and commercialize ...
... Teva: Mylan's Copaxone copy has already captured serious share Momenta and Novartis' Sandoz unit already has a 20 mg Glatopa dose on the market, but ...
... worldwide each year. With FDA-approved ANDA status and the high-quality standards of Sandoz, we anticipate leveraging the Chinese FDA's (CFDA) more recent regulations to accept ...
... $3 billion multiple sclerosis drug Gilenya; pricing challenges and biosimilar launches at Sandoz; pushing new data and tech initiatives across the company; jacking up growth ...
... in a net increase of 1.4 percentage points to 30.5% of net sales.Sandoz net sales were USD 2.6 billion (0%, -4% cc) in the fourth ...
... A major deal between Novartis subsidiary Sandoz and Bangalore, India-based biosimilar player Biocon confirms the rise of these close ...
... The FDA has accepted for review Sandoz's proposed biosimilar of AbbVie's blockbuster anti-TNF drug Humira, the company announced yesterday, ...
... Novartis International AG / Sandoz announces exclusive global collaboration with Biocon on next-generation biosimilars . Processed and ...
... Novartis International AG / Sandoz regulatory submission for proposed biosimilar adalimumab accepted by FDA . Processed and ...
... is valid. The Federal Circuit also affirmed the district court's finding that Sandoz' proposed generic version of COMBIGAN does not infringe the '149 and '976 ...
... is valid. The Federal Circuit also affirmed the district court's finding that Sandoz' proposed generic version of COMBIGAN® does not infringe the '149 and '976 ...
... competition with the likes of Stada and Nestlé, reports say. Meanwhile, Novartis’ Sandoz, which is feeling the burn—along with the rest of its generics industry ...
... until April 1, 2032. These same patents are similarly being asserted against Sandoz Inc. and Lupin Ltd. in Hatch-Waxman litigation planned for trial in mid-2019 ...
... Neulasta [1]. The Phase I study, conducted in healthy volunteers, confirmed that Sandoz biosimilar pegfilgrastim matches the reference biologic in terms of PK, PD, safety ...
... study demonstrates matching pharmacokinetic (PK), pharmacodynamic (PD), safety and immunogenicity profiles of Sandoz biosimilar pegfilgrastim and reference medicine * Pegfilgrastim is a long-acting version of ...
... preliminary talks with generic drug manufacturers such as Mylan myl and Novartis’s Sandoz. The report gave Mylan’s stock price a 4.5% pop in after-hours trading. ...
... YASTEST * Sandoz strengthens position as global leader in biosimilars with new immunology data from ...
... clarified and addressed, the drugmaker added. Hikma’s lengthy delay could make Novartis’ Sandoz a come-from-behind winner in the race to bring a cheap copy of ...
... EQUIRA study1. The Phase III comparative safety and efficacy study shows that Sandoz biosimilar Erelzi(etanercept-szzs) matches the reference medicine Enbrel, in terms of efficacy and ...
Subscribe now for full coverage on Sandoz, Inc.
Start My Free Trial